Question 1

What was Indraprastha Medical Corporation's net profit in Q2 FY27?

Accepted Answer

Consolidated net profit was ₹53.6 crore, up 8.3% from ₹49.5 crore in Q2 FY26 and down 4.1% from ₹55.9 crore in Q1 FY27.

Question 2

What was Indraprastha Medical Corporation's revenue in Q2 FY27?

Accepted Answer

Revenue from operations was ₹413 crore, up 8.4% year on year and up 1.6% from the previous quarter.

Question 3

What was Indraprastha Medical Corporation's EPS in Q2 FY27?

Accepted Answer

Basic earnings per share were ₹5.84, against ₹5.40 in Q2 FY26.

Question 4

How were Indraprastha Medical Corporation's Q2 FY27 results?

Accepted Answer

Both grew from a year earlier: net profit was up 8.3% at ₹53.6 crore and revenue was up 8.4% at ₹413 crore. The operating margin was 15.8%, down 0.1 percentage points from 15.9% a year earlier. Against Q1 FY27, net profit was down 4.1% and revenue up 1.6%.

Question 5

What was Indraprastha Medical Corporation's operating margin in Q2 FY27?

Accepted Answer

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹65.2 crore, a margin of 15.8%, against 16.8% in Q1 FY27 and 15.9% in Q2 FY26. EBITDA was ₹77.4 crore, 18.8% of revenue.

Question 6

What was Indraprastha Medical Corporation's net profit in the first half of FY27?

Accepted Answer

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹109 crore, up 8.4% from ₹101 crore in the same months a year earlier. Revenue from operations was ₹819 crore, up 9.8%.

Question 7

What is Indraprastha Medical Corporation's net profit margin?

Accepted Answer

Indraprastha Medical Corporation's net profit margin was 13.0% in Q2 FY27 (net profit as a share of revenue from operations), against 13.0% in Q2 FY26 (unchanged). For FY26 as a whole it was 12.4%.

Question 8

What was Indraprastha Medical Corporation's net profit in FY26?

Accepted Answer

Consolidated net profit was ₹184 crore in FY26 (April 2025–March 2026), up 14.1% from ₹161 crore in FY25. It was ₹124 crore in FY24 and ₹86.2 crore in FY23: up 113.1% over three years, 28.7% a year on average.

Question 9

What was Indraprastha Medical Corporation's revenue in FY26?

Accepted Answer

Revenue from operations was ₹1,483 crore in FY26 (April 2025–March 2026), up 9.3% from ₹1,356 crore in FY25. It was ₹1,245 crore in FY24 and ₹1,099 crore in FY23: up 34.9% over three years, 10.5% a year on average.

Question 10

How has Indraprastha Medical Corporation's profit changed over the last four quarters?

Accepted Answer

Net profit by quarter: ₹41 crore in Q3 FY26, ₹41.7 crore in Q4 FY26, ₹55.9 crore in Q1 FY27 and ₹53.6 crore in Q2 FY27. That is ₹192 crore over the four quarters, up 10.0% from ₹175 crore in the four quarters before. Revenue from operations: ₹372 crore, ₹365 crore, ₹406 crore and ₹413 crore.

Question 11

When did Indraprastha Medical Corporation announce its Q2 FY27 results?

Accepted Answer

On Thursday, 29 October 2026 at 4:39 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 1 November 2025.

Question 12

When will Indraprastha Medical Corporation announce its Q3 FY27 results?

Accepted Answer

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Question 13

Where do these Indraprastha Medical Corporation figures come from?

Accepted Answer

From Indraprastha Medical Corporation's own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 29 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Expenses
	413	406	365	372	381	365	334	325	350	348	315	306	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	8.6	8.4	7.3	7.2	7.4	6.9	6.4	5.1	6.1	5.1	4.9	4.3
	421	415	372	379	388	372	340	330	356	353	320	311
	67.4	70.1	64.3	63.8	65.5	62.8	59.1	56.2	56.2	58.9	55.5	50.5
	78.5	73.0	74.2	74.9	73.6	65.0	66.7	72.2	71.6	66.6	64.8	66.5
	1.7	1.7	1.5	1.5	1.5	1.6	1.5	1.6	1.6	1.6	1.6	0.9
	12.3	11.8	11.3	11.3	10.9	10.2	10.9	11.2	11.2	11.0	10.2	10.0
	189	183	166	171	171	164	147	144	158	155	146	142
	349	340	317	322	322	304	285	286	299	293	278	270
	77.4	79.8	60.5	62.0	71.3	73.2	61.3	52.2	63.6	67.1	48.4	47.3
	65.2	68.1	49.2	50.7	60.5	63.0	50.4	41.0	52.5	56.1	38.2	37.3
Profit
	72.1	74.8	55.0	56.4	66.3	68.3	55.3	44.5	56.9	59.6	41.6	40.7
	72.1	74.8	55.0	56.4	66.3	68.3	55.3	44.5	56.9	59.6	41.6	40.7
	16.9	19.7	11.5	12.6	16.4	17.4	17.1	11.9	15.2	15.2	9.2	11.7
	1.6	−0.7	1.8	2.8	0.5	−0.6	−2.8	−0.2	−0.7	−0.4	1.2	−0.5
	18.5	19.0	13.3	15.4	16.9	16.9	14.3	11.7	14.5	14.8	10.4	11.2
	53.6	55.9	41.7	41.0	49.5	51.5	41.0	32.8	42.4	44.8	31.2	29.4
	53.6	55.9	41.7	41.0	49.5	51.5	41.0	32.8	42.4	44.8	31.2	29.4
	−1.0	2.3	−1.1	0.5	−2.5	4.5	−1.5	−0.1	−1.2	2.0	1.0	1.5
	52.6	58.1	40.6	41.5	47.0	55.9	39.5	32.7	41.2	46.8	32.1	30.9
Per share
	₹5.84	₹6.09	₹4.55	₹4.47	₹5.40	₹5.61	₹4.47	₹3.58	₹4.63	₹4.88	₹3.40	₹3.21
	₹5.84	₹0.00	₹4.55	₹4.47	₹5.40	₹5.61	₹4.47	₹3.58	₹4.63	₹4.88	₹3.40	₹3.21
Other comprehensive income — detail
	−1.0	2.3	−1.1	0.5	−2.5	4.5	−1.5	—	—	—	—	—
	−1.3	3.0	−1.5	0.6	−3.3	6.0	−2.0	−0.2	−1.6	2.6	1.3	1.9
	−0.3	0.8	−0.4	0.2	−0.8	1.5	−0.5	—	—	—	—	—
	—	—	—	—	—	—	—	−0.0	−0.4	0.7	0.3	0.5
Per share — as-filed variants
	₹5.84	₹6.09	₹4.55	₹4.47	₹5.40	₹5.61	₹4.47	₹3.58	₹4.63	₹4.88	₹3.40	₹3.21
	₹5.84	₹0.00	₹4.55	₹4.47	₹5.40	₹5.61	₹4.47	₹3.58	₹4.63	₹4.88	₹3.40	₹3.21
Regulatory disclosures — filed alongside, not part of the P&L
	76.7	—	81.2	—	84.5	—	78.0	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	345	336	301	308	316	302	275	269	294	289	259	256
	83.7%	82.7%	82.4%	82.8%	82.8%	82.8%	82.3%	82.7%	83.9%	83.1%	82.4%	83.5%
Adjusted (ex-exceptional items) — derived
	72.1	74.8	55.0	56.4	66.3	68.3	55.3	44.5	56.9	59.6	41.6	40.7
	53.6	55.9	41.7	41.0	49.5	51.5	41.0	32.8	42.4	44.8	31.2	29.4
	₹5.84	₹6.09	₹4.55	₹4.47	₹5.40	₹5.61	₹4.47	₹3.58	₹4.63	₹4.88	₹3.40	₹3.21

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	306.5	314.7	347.9	349.8	324.9	333.8	365.1	381.0	371.6	364.8	406.2	412.9
Other Income	4.3	4.9	5.1	6.1	5.1	6.4	6.9	7.4	7.2	7.3	8.4	8.6
Total Income	310.7	319.6	353.0	355.9	330.1	340.1	372.0	388.4	378.8	372.1	414.6	421.4
Expenses
+ Cost of Materials Consumed	50.5	55.5	58.9	56.2	56.2	59.1	62.8	65.5	63.8	64.3	70.1	67.4
+ Employee Benefit Expense	66.5	64.8	66.6	71.6	72.2	66.7	65.0	73.6	74.9	74.2	73.0	78.5
+ Finance Costs	0.9	1.6	1.6	1.6	1.6	1.5	1.6	1.5	1.5	1.5	1.7	1.7
+ Depreciation & Amortisation	10.0	10.2	11.0	11.2	11.2	10.9	10.2	10.9	11.3	11.3	11.8	12.3
+ Other Expenses	142.2	146.0	155.2	158.3	144.4	146.6	164.1	170.7	171.0	165.8	183.3	189.5
Total Expenses	270.1	278.1	293.4	298.9	285.5	284.8	303.7	322.1	322.4	317.1	339.8	349.3
EBITDA	47.3	48.4	67.1	63.6	52.2	61.3	73.2	71.3	62.0	60.5	79.8	77.4
EBIT	37.3	38.2	56.1	52.5	41.0	50.4	63.0	60.5	50.7	49.2	68.1	65.2
Profit
PBT before Exceptional Items	40.7	41.6	59.6	56.9	44.5	55.3	68.3	66.3	56.4	55.0	74.8	72.1
Pretax Income	40.7	41.6	59.6	56.9	44.5	55.3	68.3	66.3	56.4	55.0	74.8	72.1
+ Current Tax	11.7	9.2	15.2	15.2	11.9	17.1	17.4	16.4	12.6	11.5	19.7	16.9
+ Deferred Tax	-0.5	1.2	-0.4	-0.7	-0.2	-2.8	-0.6	0.5	2.8	1.8	-0.7	1.6
Tax Expense	11.2	10.4	14.8	14.5	11.7	14.3	16.9	16.9	15.4	13.3	19.0	18.5
Net Income	29.4	31.2	44.8	42.4	32.8	41.0	51.5	49.5	41.0	41.7	55.9	53.6
+ Net Income — Continuing Ops	29.4	31.2	44.8	42.4	32.8	41.0	51.5	49.5	41.0	41.7	55.9	53.6
+ Other Comprehensive Income	1.5	1.0	2.0	-1.2	-0.1	-1.5	4.5	-2.5	0.5	-1.1	2.3	-1.0
Total Comprehensive Income	30.9	32.1	46.8	41.2	32.7	39.5	55.9	47.0	41.5	40.6	58.1	52.6
Per Share
Basic EPS	3.21	3.40	4.88	4.63	3.58	4.47	5.61	5.40	4.47	4.55	6.09	5.84
Diluted EPS	3.21	3.40	4.88	4.63	3.58	4.47	5.61	5.40	4.47	4.55	0.00	5.84
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-1.5	4.5	-2.5	0.5	-1.1	2.3	-1.0
+ Items NOT to be Reclassified to P&L	1.9	1.3	2.6	-1.6	-0.2	-2.0	6.0	-3.3	0.6	-1.5	3.0	-1.3
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	-0.5	1.5	-0.8	0.2	-0.4	0.8	-0.3
+ Tax on Items NOT to be Reclassified — alt tag	0.5	0.3	0.7	-0.4	-0.0	—	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	3.21	3.40	4.88	4.63	3.58	4.47	5.61	5.40	4.47	4.55	6.09	5.84
Diluted EPS — Continuing Operations	3.21	3.40	4.88	4.63	3.58	4.47	5.61	5.40	4.47	4.55	0.00	5.84
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	78.0	—	84.5	—	81.2	—	76.7
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	256.0	259.2	288.9	293.6	268.8	274.6	302.2	315.6	307.9	300.5	336.0	345.4
Gross Margin %	83.53	82.35	83.06	83.93	82.71	82.29	82.79	82.82	82.84	82.37	82.73	83.67
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	40.7	41.6	59.6	56.9	44.5	55.3	68.3	66.3	56.4	55.0	74.8	72.1
Net Income Adj (tax-effected)	29.4	31.2	44.8	42.4	32.8	41.0	51.5	49.5	41.0	41.7	55.9	53.6
EPS Adj	3.21	3.40	4.88	4.63	3.58	4.47	5.61	5.40	4.47	4.55	6.09	5.84
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	91.7	91.7	91.7	91.7	91.7	91.7	91.7	91.7	91.7	91.7	91.7	91.7

Indraprastha Medical Corporation quarterly results

Every quarter

Indraprastha Medical Corporation Limited

Indraprastha Medical Corporation Q2 FY27 results (July–September 2026)

Q2 FY27 at a glance · consolidated

Questions